The Biotech company Evaxion Biotech, EVAX, who develop drugs based on AI platforms, is poised to publish data from its phase 1/2a trials of EVX-01 and EVX-02 in the first half of 2021.
According to Yahoo Finance there are currently two analysts with price targets for the share, $18 and $23.
Evaxion is an AI-immunology platform company decoding the human immune...
EVAX - Evaxion
Evaxion is an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases.
Evaxion have developed an AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system...
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on 11 August, 2008 and is headquartered in Copenhagen, Denmark.